Skip Ribbon Commands
Skip to main content

Motility Monitoring

Clinical Utility

With SmartPill’s proven clinical utility, you can have the confidence that you are providing your patients with a convenient and comfortable test that provides detailed information about the patient’s GI tract.  SmartPill’s clinical advantages include:
Greater sensitivity than GES and ROM:
  • SmartPill has an enhanced sensitivity of 0.65 compared to GES sensitivity of 0.44 in the detection of gastroparesis1
  • SmartPill has an enhanced sensitivity of 0.46 compared to ROM sensitivity of 0.37 in the detection of slow transit constipation2
Full GI tract profile provides direction for proper drug therapy in the presence of overlapping symptoms:
  • 18% of gastroparetic patients also have delayed colonic transit3
  • 18% of patients with chronic constipation also have delayed gastric emptying4
  • 13% of refractory patients also have delayed small bowel transit5
Standardized results:
  • SmartPill provides standardized results utilizing the SmartBar standardized meal6
  • Radiologic exams do not provide standard protocol7
Clinically useful in assessing patients with suspected dysmotility:6
  • SmartPill detected a generalized motility disorder in 51% of patients and influenced management in 30% of patients with lower GI disorders and 88% of patients with upper GI disorders
  • SmartPill provides new diagnostic information in 50% of patients, leading to a change in patient management
Reduces testing by replacing three tests:8
  • SmartPill’s whole gut motility profile eliminates the need for segmental transit studies
  • Can replace GES, ROM and Whole Gut Scintigraphy
  • Can reduce the cost of separate procedures and associated facility fees by 50%
1Kuo et al. Comparison of Gastric Emptying of a Nondigestible Capsule to a Radio-Labelled Meal in Healthy and Gastroparetic Subjects. Aliment Pharmacol Ther 2008;27:186-196.
2Rao et al. Investigation of Colonic and Whole-Gut Transit with Wireless Motility Capsule and Radiopaque Markers in Constipation. Clin Gastroenterol Hepatol 2009:7:537-544.

3Camilleri et al. Wireless pH-Motility Capsule for Colonic Transit: Prospective Comparison with Radiopaque Markers in Chronic Constipation. Neurogastroenterol Motil 2010;22:874-882.
4Sarosiek et al. The Assessment of Regional Gut Transit Times in Healthy Controls and Patients with Gastroparesis Using Wireless Motility Technology. Aliment Pharmacol Ther 2009;31:313-322.

5Rao et al. Diagnostic Utility of Wireless Motility Capsule in Gastrointestinal Dysmotility.
J Clin Gastroentrol 2011;45(8):684-690.
6Rao et al. Evaluation of Gastrointestinal Transit in Clinical Practice: Position Paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterol Motil 2011; 23:8-23.
7Tran K, et al. Evaluation of Regional and Whole Gut Motility Using the Wireless Motility Capsule: relevance in Clinical Practice. Therap Adv Gastroenterol 2012;5(4):249-260.
8Moshiree B. Case Presentation Illustrating Use of Wireless Motility Capsule, 2010 Joint International Neurogastroenterology and Motility Conference.